ACR open rheumatology · 2026
Quantification of Vascular Burden on Cranial Vessel Wall Magnetic Resonance Imaging and Ophthalmic Complications in Giant Cell Arteritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang David L, Cao Quy, Liu Fang, McWilliams Tara, Rebello Ryan, Tamhankar Madhura A, Banerjee Shubhasree, Liang Rui, Kurtz Robert M, Baker Joshua F, Amudala Naomi, Fan Zhaoyang, Song Jae W, Merkel Peter A, Morris Jeffrey, Rhee Rennie L
Аннотация
OBJECTIVE: There is a need for measures of disease severity for giant cell arteritis (GCA), which may enable identification of high-risk subgroups (eg, ophthalmic complications) and individualized approaches to therapy. We derived a continuous score using data from cranial vessel wall magnetic resonance imaging (VW-MRI) to quantify vascular burden in GCA and assessed the score's association with ophthalmic manifestations.
METHODS: Patients with suspected new or relapsing GCA underwent cranial VW-MRI plus dedicated orbital MRI. A radiologist assessed VW-MRI enhancement of seven cranial structures bilaterally. Using a generalized linear mixed-effects model, a continuous MRI-derived patient-level score (range 1-10) of disease extent was developed: the Cranial Artery MRI Score for GCA (CAMRIS-GCA). CAMRIS-GCA was compared between clinical diagnosis (ocular GCA, nonocular GCA, or non-GCA) and patients with versus without ocular inflammation on MRI (defined as ophthalmic artery or optic nerve sheath enhancement).
RESULTS: Seventy-four patients (17 ocular GCA, 16 nonocular GCA, and 41 non-GCA) were included. CAMRIS-GCA increased linearly across clinically defined groups of non-GCA, nonocular GCA, and ocular GCA (CAMRIS-GCA median 0.6 [interquartile range (IQR) 0-1.7] vs median 2.5 [IQR 0.5-6.6] vs median 4.8 [IQR 2.1-8.5]; P < 0.01). Patients with orbital inflammation on MRI (with or without visual symptoms) had a higher median CAMRIS-GCA compared to patients with negative orbital MRI (median 6.7 [IQR 5.6-8.5] vs median 0.4 [IQR 0-1.6]; P < 0.01).
CONCLUSION: This proof-of-concept study introduces a quantitative MRI-derived vascular burden score in GCA and demonstrates its association with ophthalmic involvement. These early findings suggest that cranial VW-MRI may offer a prognostic value in identifying patients at risk for vision-threatening disease.
METHODS: Patients with suspected new or relapsing GCA underwent cranial VW-MRI plus dedicated orbital MRI. A radiologist assessed VW-MRI enhancement of seven cranial structures bilaterally. Using a generalized linear mixed-effects model, a continuous MRI-derived patient-level score (range 1-10) of disease extent was developed: the Cranial Artery MRI Score for GCA (CAMRIS-GCA). CAMRIS-GCA was compared between clinical diagnosis (ocular GCA, nonocular GCA, or non-GCA) and patients with versus without ocular inflammation on MRI (defined as ophthalmic artery or optic nerve sheath enhancement).
RESULTS: Seventy-four patients (17 ocular GCA, 16 nonocular GCA, and 41 non-GCA) were included. CAMRIS-GCA increased linearly across clinically defined groups of non-GCA, nonocular GCA, and ocular GCA (CAMRIS-GCA median 0.6 [interquartile range (IQR) 0-1.7] vs median 2.5 [IQR 0.5-6.6] vs median 4.8 [IQR 2.1-8.5]; P < 0.01). Patients with orbital inflammation on MRI (with or without visual symptoms) had a higher median CAMRIS-GCA compared to patients with negative orbital MRI (median 6.7 [IQR 5.6-8.5] vs median 0.4 [IQR 0-1.6]; P < 0.01).
CONCLUSION: This proof-of-concept study introduces a quantitative MRI-derived vascular burden score in GCA and demonstrates its association with ophthalmic involvement. These early findings suggest that cranial VW-MRI may offer a prognostic value in identifying patients at risk for vision-threatening disease.